Velimogene aliplasmid

Expert Opinion on Biological Therapy

Volumn 10, Issue 5, 2010, Pages 841-851

  Soares, Heloisa P ^a   Lutzky, Jose ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Mount Sinai Comprehensive Cancer Center   (United States)

Author keywords

Allovectin; Immunotherapy; Melanoma; Vaccines; Velimogene aliplasmid

Indexed keywords

ALLOVECTIN 7; ALPHA INTERFERON; BCG VACCINE; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; ROSE BENGAL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID;

ABDOMINAL PAIN; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; INJECTION SITE PAIN; KIDNEY CARCINOMA; LIVER METASTASIS; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BETA 2-MICROGLOBULIN; CANCER VACCINES; DNA, RECOMBINANT; EVIDENCE-BASED MEDICINE; GENE THERAPY; HLA-B7 ANTIGEN; HUMANS; IMMUNOTHERAPY; LIPIDS; MELANOMA; TREATMENT OUTCOME;

EID: 77951112009     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.481280     Document Type: Review

References (65)

1. Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893;105:487-511
2. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529-564
3. Coley W. The treatment of malignant inoperable tumors with the mixed toxins of erysipelas and Bacillus prodigiosus. M Weissenbruch, Brussels; 1914
4. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325:1205-1209
5. Mori K, Lamm DL, Crawford ED. A trial of bacillus Calmette-Guerin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study. Urol Int 1986;41:254-259 (Pubitemid 17175303)
6. Prendergast G, Jaffe E. Cancer immunotherapy. Elsevier, Oxford, UK; 2007
7. Hu X, Chakraborty NG, Sporn JR, et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-2483
8. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332
9. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327
10. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87(13):982-990
11. Petrella T, Quirt I, Verma S, et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33:484-496 (Pubitemid 47333669)
12. Schwartzentruber D, Lawson D, Richards J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2009;27:abstract 9011
13. Spitler LE, Weber RW, Allen RE, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother 2009;32:632-637
14. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164
15. Bornstein RS, Mastrangelo MJ, Sulit H, et al. Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr 1973;39:213-220
16. Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 2008;13:295-308
17. Green DS, Bodman-Smith MD, Dalgleish AG, et al. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007;156:337-345
18. Ribas A, Comin-Anduix B, Jalil J, et al. Combination of dendritic cell (DC) vaccination with CTLA4 blockade in patients (pts) with metastatic melanoma: a phase 1 clinical trial [abstract 2537]. AACR Meeting Abstracts 2008
19. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15:341-349
20. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-3094
21. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003;22:3188-3192
22. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-5771
23. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003;89:1620-1626
24. Von Wussow P, Block B, Hartmann F, et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988;61:1071-1074
25. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-990
26. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996;6:247-255
27. Steinmann A, Funk JO, Schuler G, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-556
28. Foote MC, Burmeister BH, Thomas J, et al. A novel treatment for metastatic melanoma with intralesional rose Bengal and radiotherapy: a case series. Melanoma Res 2010;20:48-51
29. Wiener M, Damian DL, Thompson JF. Systemic phototoxicity following intralesional rose bengal for subcutaneous melanoma metastases. Dermatology 2008;216:361-362
30. Robinson H. DNA vaccines. In: Austen F, Burakoff S, Rosen F, editors, Therapeutic immunology. 2nd edition. Wiley-Blackwell, Boston; 2001. p. 430-440
31. Allovectin-7. Vical Incorporated. San Diego, CA. Available from: http://www.vical.com/products/ cancer-therapies/allovectin-7.htm [Last accessed 27 March 2010]
32. Galanis E. Technology evaluation: Allovectin-7, Vical. Curr Opin Mol Ther 2002;4:80-87
33. Plautz GE, Yang ZY, Wu BY, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645-4649
34. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-15393
35. Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999;5:2766-2772
36. Horton HM, Dorigo O, Hernandez P, et al. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol 1999;163:6378-6385
37. Zhao H, Hemmi H, Akira S, et al. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther 2004;9:241-248
38. Parker SE, Vahlsing HL, Serfilippi LM, et al. Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther 1995;6:575-590
39. Lew D, Parker SE, Latimer T, et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995;6:553-564
40. Horn NA, Meek JA, Budahazi G, et al. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther 1995;6:565-573
41. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11311
42. Silver H, Klassa R, Bally J, et al. Phase I gene therapy of HLA-B7 transduction by direct injection in malignant melanoma [abstract 2337]. AACR Meeting Abstracts 1996
43. Rubin J, Galanis E, Pitot HC, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997;4:419-425
44. Gleich LL, Gluckman JL, Armstrong S, et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a Phase-1 trial. Arch Otolaryngol Head Neck Surg 1998;124:1097-1104
45. Hersh EM, Stopeck A, Klassa R, et al. Allovectin-7 (hla-b7/[beta]2m plasmid dna/lipid complex) therapy in metastatic malignant melanoma, Phase II studies. Proc Am Soc Clin Oncol 1998;17:abstract 1658
46. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7:2285-2291
47. Richards J, Bedikian A, Gonzalez R, et al. High-dose Allovectin-7 in patients with advanced metastatic melanoma: final Phase 2 data and design of Phase 3 registration trial. Proc Am Soc Clin Oncol 2005;23:abstract 7543
48. Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010 (In Press)
49. Gonzalez R, Hutchins L, Nemunaitis J, et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16:521-526
50. Gleich LL, Gluckman JL, Nemunaitis J, et al. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:775-779
51. Richards J, Thompson J, Atkins M, et al. A controlled, randomized phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2002;21:abstract 1380
52. Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008;8:839-844
53. Vical Incorporated. A Phase 3 clinical trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7 Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanoma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009. Available from: http://clinicaltrials.gov/ct2/show/ NCT00395070 [Last accessed 27 March 2010] NLM Identifier: NCT00395070
54. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249
55. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748-5754
56. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116
57. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-4745
58. Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12:1114-1123 (Pubitemid 350007023)
59. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-2830
60. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. Proc Am Soc Clin Oncol 2009;27:abstract 9000
61. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. Proc Am Soc Clin Oncol 2009;27:abstract 9001
62. Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009;15:169-173
63. Sznol M. Betting on immunotherapy for melanoma. Curr Oncol Rep 2009;11:397-404
64. Lee SC, Lopez-Albaitero A, Ferris RL. Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. Curr Oncol Rep 2009;11:156-162
65. Wu AA, Niparko KJ, Pai SI. Immunotherapy for head and neck cancer. J Biomed Sci 2008;15:275-289